ArticlePlant foods for human nutrition (Dordrecht, Netherlands)2025
Mechanism of Red Yeast Rice in the Improvement of Atherosclerosis in Apolipoprotein E-deficient Mice Explored Through Metabolomics Combined with Serum Pharmacochemistry and Network Pharmacology.
Article in Plant foods for human nutrition (Dordrecht, Netherlands), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Red Yeast Rice (RYR), the fermentation of cooked rice kernels with Monascus purpureus, has been traditionally and increasingly applied to alleviate atherosclerosis (AS). Nonetheless, the precise mechanisms underlying its therapeutic effects in AS treatment remain elusive. Metabolomics combined with serum pharmacochemistry and network pharmacology was utilized to explore the potential molecular mechanisms by which RYR improves AS. RYR showed a significant inhibitory effect on metabolic dysfunction in mice. Specifically, through metabolomics analysis, 45 metabolic biomarkers were identified, which are associated with 5 metabolic pathways, particularly arachidonic acid metabolism. Serum pharmacochemistry identified 11 absorbed constituents of RYR that entered the bloodstream. Subsequent correlation analysis determined that 10 constituents may serve as bioactive ingredients significantly associated with the metabolic biomarkers. Network pharmacology identified 5 core targets and enriched 129 representative pathways, among which the PI3K/AKT signaling pathway received the highest score. Molecular docking verified that there existed strong binding energy between the absorbable components and pivotal targets. The pharmacodynamic evaluation results verified that the down-regulation of PI3K and p-AKT expressions in the PI3K/AKT pathway served as the underlying mechanism of RYR in addressing AS. These findings underscore the pharmacodynamic components, pivotal targets, and pathways of RYR in AS treatment, as well as the development of functional foods involving RYR.
Indexed as
Identifiers
40531242What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.